Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (CORT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cort · stock forecast · 26 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 26 Wall Street analysts in the past 3 months
Buy
26 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$135
Consensus
$83.00
+14.3% upside
Low
$30.00
Median: $91.5 · Last Close: $72.62
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$83.00
14.3% upside
High Target
$135
85.9%
Low Target
$30
-58.7%
Current Price
$72.62
as of today
Based on analyst price targets, the CORT stock price prediction for the next 12 months ranges from $30 to $135. The consensus CORT price forecast of $83.00 implies 14.3% upside from the current price of $72.62.
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $76.25 | ↑ 5.00% |
1-day model range: $75.47–$77.03. Peak: $77.03 (+5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CORT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-28 | Canaccord Genuity | Maintains | Buy→Buy |
| 2026-05-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-13 | UBS | Upgrade ↑ | Neutral→Buy |
| 2026-05-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-01 | Piper Sandler | Maintains | Overweight→Overweight |
| 2026-03-26 | Wolfe Research | Upgrade ↑ | Underperform→Peer Perform |
| 2026-03-26 | Canaccord Genuity | Maintains | Buy→Buy |
| 2026-03-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Corcept Therapeutics Incorporated (CORT) stock. Of the recent 114 rating actions, 6 were upgrades and 18 were downgrades. 26 analysts currently cover CORT.
Analyst Recommendation Trends
CORT analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 5 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$977M
↓ 49.0% YoY
Revenue Next Year
$1.4B
↑ 40.1% YoY
EPS This Year
$0.59
EPS Next Year
$2.61
↑ 346.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast CORT EPS of $0.59 for the current fiscal year, based on estimates from 4 analysts. The CORT revenue forecast is $977M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CORT stock forecast is supported by two independent data sources: analyst consensus ratings from 26 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CORT price target is $83.00 (+14.3% upside), with an analyst consensus of Buy.
The CORT short-term stock prediction for tomorrow is $76.25 (+5.00%).
Corcept Therapeutics Incorporated trades on NASDAQ under the ticker CORT. The CORT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 54% of covering analysts.
Frequently asked questions
CORT forecast · 8 questionsAccording to 26 Wall Street analysts, the average 12-month CORT price target is $83.00, with a high forecast of $135.00 and a low of $30.00. The median price target is shown in the chart above when available. This implies +14.3% potential upside from the current price of $72.62.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.